

SCIENTIFIC REPORTS

OPEN

Altered B-lymphopoiesis in mice with deregulated thrombopoietin signaling

Amanda E. Au^{1,2}, Marion Lebois¹, Starling A. Sim^{1,2}, Ping Cannon¹, Jason Corbin¹, Pradnya Gangatirkar¹, Craig D. Hyland¹, Diane Moujalled¹, Angelika Rutgersson^{1,3}, Fatme Yassinson^{1,3}, Benjamin T. Kile^{1,2,5}, Kylie D. Mason⁴, Ashley P. Ng^{1,2}, Warren S. Alexander^{1,2} & Emma C. Josefsson^{1,2}

Received: 27 March 2017

Accepted: 12 October 2017

Published online: 02 November 2017

Thrombopoietin (TPO) is the master cytokine regulator of megakaryopoiesis. In addition to regulation of megakaryocyte and platelet number, TPO is important for maintaining proper hematopoietic stem cell (HSC) function. It was previously shown that a number of lymphoid genes were upregulated in HSCs from *Tpo*^{-/-} mice. We investigated if absent or enhanced TPO signaling would influence normal B-lymphopoiesis. Absent TPO signaling in *Mpl*^{-/-} mice led to enrichment of a common lymphoid progenitor (CLP) signature in multipotential lineage-negative Sca-1⁺c-Kit⁺ (LSK) cells and an increase in CLP formation. Moreover, *Mpl*^{-/-} mice exhibited increased numbers of PreB2 and immature B-cells in bone marrow and spleen, with an increased proportion of B-lymphoid cells in the G1 phase of the cell cycle. Conversely, elevated TPO signaling in *Tpo*^{Tg} mice was associated with reduced B-lymphopoiesis. Although at steady state, peripheral blood lymphocyte counts were normal in both models, *Mpl*^{-/-} Eμ-*myc* mice showed an enhanced preneoplastic phase with increased numbers of splenic PreB2 and immature B-cells, a reduced quiescent fraction, and augmented blood lymphocyte counts. Thus, although *Mpl* is not expressed on lymphoid cells, TPO signaling may indirectly influence B-lymphopoiesis and the preneoplastic state in *Myc*-driven B-cell lymphomagenesis by lineage priming in multipotential progenitor cells.

Platelets are produced from large precursor cells in the bone marrow called megakaryocytes. The process by which megakaryocytes produce platelets is unique and involves polyploidisation and shedding of platelets into the blood stream¹. Thrombopoietin (TPO), produced mainly in the liver, stimulates both megakaryocyte colony formation and enhances megakaryocyte maturation in the bone marrow leading to increased platelet production. TPO binds to its receptor, TPOR/MPL, which is expressed on hematopoietic stem cells (HSCs), megakaryocytes and platelets². Circulating TPO concentrations are controlled by MPL via receptor-mediated internalization and degradation^{3,4}, and in part by sensing of senescent platelets by the Ashwell-Morell receptor in the liver⁵. *Mpl*^{-/-} mice exhibit platelet counts ~10% of wild-type levels⁶, while *Tpo*^{Tg} transgenic mice, engineered to overexpress TPO in the liver, have ~3.5 times higher platelet counts⁷ compared to wild-type mice. In addition to regulating megakaryopoiesis, TPO is known to affect HSC number and quiescence⁷. A low level of TPO leads to reductions in total HSCs, but with more of them in active cycle. This is evident in *Mpl* deficient mice, which not only exhibit thrombocytopenia, but also have increased cycling and a decline in the number of HSCs with age^{8–10}. Conversely, a high TPO level leads to a greater proportion of quiescent HSCs⁷.

It has previously been reported that down-regulation of *Mpl* marks the transition from pluripotent to lymphoid-primed multipotent hematopoietic progenitor cells¹¹ and that a number of lymphoid genes are upregulated in HSCs from *Tpo*^{-/-} mice¹². Here, we compared the effects of absent or enhanced TPO signaling on

¹The Walter and Eliza Hall Institute of Medical Research, 1 G Royal Parade, VIC 3052, Australia. ²The University of Melbourne, Department of Medical Biology, 1 G Royal Parade, VIC 3052, Australia. ³Department of Pharmacology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, P.O. Box 431, 405 30, Gothenburg, Sweden. ⁴The University of Melbourne, Faculty of Medicine, Dentistry and Health Sciences, Melbourne, VIC, Australia. ⁵Present address: Monash Biomedicine Discovery Institute, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC 3800, Australia. Correspondence and requests for materials should be addressed to E.C.J. (email: josefsson@wehi.edu.au)




Figure 1. Lymphoid lineage priming in *Mpl*^{-/-} LSKs. **(a)** Hematopoietic stem and progenitor cells per femur relative to WT in 4–5 weeks old mice. WT (n = 8), *Mpl*^{-/-} (n = 6) and *Tpo*^{Tg} (n = 7). Mean ± SEM. Statistical significance was generated by Student's unpaired t-test. **p* < 0.05. **(b)** Barcode plot of the CLP gene signature in *Mpl*^{-/-} and **(c)** *Tpo*^{Tg} LSKs. Gene set tests were performed using gene set obtained for the CLP population from the Hemopedia atlas¹⁸.

steady-state B-lymphopoiesis and in a model of over-active B-lymphopoiesis, the *Eu-myc* transgenic mice, which display a characteristic preneoplastic phase with expansion of immature Pro- and Pre-B cell populations^{13,14}. We found that, although *Mpl* is not expressed on lymphoid cells, absent TPO signaling in *Mpl*^{-/-} mice led to lineage priming of lineage-negative Sca-1⁺c-Kit⁺ (LSK) cells with increased numbers of common lymphoid progenitors (CLPs), PreB2 and immature B-cells. Additionally, *Mpl*^{-/-} *Eu-myc* mice demonstrated an enhanced preneoplastic phase that resulted in earlier disease onset. By comparison, elevated TPO signaling modestly suppressed B-lymphopoiesis and resulted in delayed disease onset in *Tpo*^{Tg} *Eu-myc* transgenic mice. Thus, despite the absence of *Mpl* expression in B-lymphoid cells, changes induced in multipotential hematopoietic progenitor cells by altered TPO signaling, including altered gene expression and lineage priming, indirectly affect B-lymphopoiesis. The effects of altered *Mpl* signaling at steady-state were confined to changes in B-lymphoid precursor cell numbers, with no alteration in circulating B cell number. However, under conditions of excess proliferation modeled using *Eu-myc* transgenic mice, the changes conferred by altered *Mpl* signaling in preneoplastic B-lymphopoiesis were sufficient to influence the onset of B-cell lymphoma.

Results

Lymphoid lineage skewing in *Mpl*^{-/-} bone marrow and spleen. In accordance with previous findings reported in adult mice^{7,15}, in the setting of increased TPO signaling, we found that 4–5 week old *Tpo*^{Tg} mice had a 4-fold increase in numbers of LSK cells and corresponding LSK subpopulations long-term HSCs (LTHSCs), short-term HSCs (STHSCs) and lymphoid-primed multipotent progenitors (LMPPs) in the bone marrow when compared to wild-type mice (Fig. 1a). While augmented numbers of CLPs and B-cell primed progenitors (BLPs), could also be observed in *Tpo*^{Tg} bone marrow, this effect was more modest (Fig. 1a, Supplementary Fig. S1). In contrast, as previously described^{7,15}, *Mpl*^{-/-} mice had a significantly reduced number of LSKs (Fig. 1a, Supplementary Fig. S1). Interestingly, despite a deficiency in the number of LSKs, numbers of CLPs and BLPs were significantly increased in *Mpl*^{-/-} bone marrow (Fig. 1a, Supplementary Fig. S1). Prior evidence had suggested




Figure 2. Lymphoid lineage priming in *Mpl*^{-/-} bone marrow and spleen. **(a)** Bone marrow and **(b)** spleen cellularity of B-cell subsets in 4–5 week old mice. WT (n = 17), *Mpl*^{-/-} (n = 16) and *Tpo*^{Tg} (n = 15). **(c–d)** K₁-67/DAPI cell cycling assessment of B-cell subsets within bone marrow and spleen of 4–5 week old WT (n = 17), *Mpl*^{-/-} (n = 17) and *Tpo*^{Tg} (n = 13) mice. Statistical significance was generated by Student's unpaired t-test. Mean \pm SEM. * $p < 0.05$; ** $p < 0.005$; *** $p < 0.001$

that lymphoid-specific gene transcription may be primed early in hematopoiesis^{16,17}. Here, we observed more specifically, that relative to wild-type LSKs, a CLP gene expression signature¹⁸ was upregulated in *Mpl*^{-/-} LSKs ($p = 0.0001$) (Fig. 1b, Supplementary Table S1) and conversely down regulated in *Tpo*^{Tg} LSKs ($p = 0.0001$) (Fig. 1c, Supplementary Table S1). In confirmation of these results, lineage priming with early B-cell progenitor ProB and PreB gene expression signatures was also observed in *Mpl*^{-/-} LSKs, and that these were conversely downregulated in *Tpo*^{Tg} LSKs (Supplementary Table S2).

To determine any functional consequences of these altered gene expression profiles, the numbers of lymphoid cells were further enumerated in *Mpl*^{-/-} and *Tpo*^{Tg} mice. In 4–5 week old mice, *Mpl* deficiency led to increased PreB2 cell numbers in bone marrow along with elevated immature B-cell numbers in bone marrow and spleen (Fig. 2a,b). In contrast, *Tpo*^{Tg} mice had reduced numbers of bone marrow ProB-PreB1, PreB2 cells and splenic mature B cells (Fig. 2a,b).

While *Mpl* is expressed on LSK cells, we found the receptor to be absent on CLPs, ProB-PreB1, PreB2, immature, and mature B cells (Supplementary Fig. S1), excluding an effect via direct TPO signaling in committed B-lineage cells. Limiting dilution assays revealed no significant difference in *in vitro* clonogenicity of purified *Mpl*^{-/-} and *Tpo*^{Tg} CLPs relative to wild-type cells (Supplementary Fig. S2). However, in the *Mpl*^{-/-} spleen, immature and mature B-cells cycled significantly more than wild-type, as indicated by an increased proportion of cells in G1 and a reduced proportion in G0 (Fig. 2d). However, changes in cell cycle status were not evident in B-lymphoid cells in *Tpo*^{Tg} mice (Fig. 2c,d), nor in *Mpl*^{-/-} bone marrow (Fig. 2c), and peripheral blood lymphocyte counts in *Mpl*^{-/-} and *Tpo*^{Tg} mice were normal (Table 1)¹⁵. Thus, although altered TPO signaling may




Figure 3. Increased lymphoproliferation in preneoplastic *Mpl* deficient mice. (a) Spleen weight (b) Lymphocyte (c) Red blood cell (RBC) and (d) platelet counts in 4–5 week old mice. n = 11–18 mice per genotype. Whiskers: Min to Max. (e) Bone marrow and (f) spleen cellularity and Pro-PreB1, PreB2, immature and mature B-cells in 4–5 week old mice assessed by flow cytometry. Data are presented as mean ± SEM. n = 11–18 mice per genotype. Statistical significance was generated by Student's unpaired t-test. **p* < 0.05; ***p* < 0.005; ****p* < 0.001

indirectly affect B-lymphopoiesis, other mechanisms were clearly contributing to circulating lymphocyte homeostasis at steady state.

TPO restricts *Eμ-myc* preneoplastic lymphoproliferation. We next investigated the changes in B-lymphopoiesis evident in *Mpl*^{-/-} and *Tpo*^{Tg} mice in the context of excess B-lymphoid proliferation in *Eμ-myc* transgenic mice¹⁴. We initially confirmed that preneoplastic *Eμ-myc* B-cell subsets did not express *Mpl* protein, when assessed by flow cytometry (Supplementary Fig. S3) as was the case for wild-type B-cell subsets. The preneoplastic phase in *Eμ-myc* mice is characterized by a polyclonal expansion of PreB cells accompanied by mild splenomegaly¹⁹. We observed that relative to 4–5 week-old *Eμ-myc* control mice, age matched *Mpl*^{-/-} *Eμ-myc* mice displayed an increase in spleen weight of 1.4-fold (Fig. 3a) which was accompanied by a 1.9-fold increase in peripheral blood lymphocyte counts (Fig. 3b). In comparison to *Eμ-myc* controls, *Mpl*^{-/-} *Eμ-myc* mice showed a modest reduction in red blood cell number, while, the number of platelets was reduced in the presence of the *Eμ-myc* transgene irrespective of whether mice were on a wild-type or *Mpl*^{-/-} background (Fig. 3c,d). In order to investigate if the observed blood lymphocyte elevation corresponded with changes in B cell precursors in the bone marrow and spleen we examined B-cell subsets and cellularity in pre-neoplastic *Eμ-myc*, *Mpl*^{-/-} *Eμ-myc* and *Tpo*^{Tg} *Eμ-myc* mice (Fig. 3e,f). We found increased spleen cellularity and a doubling in the number of PreB2 cells as well as significant increases in the numbers of immature and mature B-cells in pre-neoplastic *Mpl*^{-/-} *Eμ-myc* spleen, compared to *Eμ-myc* mice (Fig. 3f). Moreover, *Mpl*^{-/-} *Eμ-myc* mice had increased numbers of immature B-cells in the bone marrow (Fig. 3e). Conversely, pre-neoplastic *Tpo*^{Tg} *Eμ-myc* mice had reduced PreB2 cell numbers in bone marrow and spleen as well as significantly fewer immature and mature splenic B-cells compared to *Eμ-myc* control mice (Fig. 3e,f). To confirm these results, we next assessed the effect of exogenous TPO on the preneoplastic phase by administration of the TPO-mimetic Romiplostim²⁰ in *Eμ-myc* and littermate control animals starting when they were 1 week old. When mice were assessed at 5-weeks of age, platelet counts were significantly increased in animals receiving Romiplostim compared to vehicle (Fig. 4a). As expected, 5-week old vehicle treated *Eμ-myc* mice had increased lymphocyte counts, spleen cellularity and bone marrow and spleen PreB2 cells compared to wild-type control mice (Fig. 4b,c,d). Interestingly, Romiplostim treated *Eμ-myc* mice had




Figure 4. Effects of TPO-mimetic on preneoplastic phase. 1-week-old Eμ-myc mice and their wild-type littermates were injected subcutaneously every 3 days with 100 μg/kg Romiplostim or saline vehicle. At 5 weeks of age (a) platelet and (b) lymphocyte counts (c) spleen cellularity, PreB2, and immature B-cells, and (d) bone marrow cellularity, ProB-PreB1, PreB2 and Immature B-cells. n = 8–14 mice per group. Data are presented as mean ± SEM. Statistical significance was generated by Student's unpaired t-test. * $p < 0.05$; ** $p < 0.005$; *** $p < 0.001$. BM = bone marrow.

reduced lymphocyte counts, lower spleen cellularity and fewer PreB2 and immature B-cells in both bone marrow and spleen when compared to vehicle treated Eμ-myc mice (Fig. 4b,c,d).

Eμ-myc mice have previously been shown to succumb to aggressive lymphoma within 3–6 months after birth¹⁴. *Mpl*^{-/-}, *Tpo*^{Tg} and wild-type mice aged up to 1 year showed no signs of tumor development during the course of the study (Fig. 5a). However, the changes conferred by altered *Mpl* signaling in preneoplastic B-lymphopoiesis were sufficient to influence the onset of B cell lymphoma in Eμ-myc mice. *Mpl*^{-/-} Eμ-myc mice became unwell with a reduced median survival of 76.5 days, compared to conventional Eμ-myc mice (87 days, $p < 0.0001$) (Fig. 5a). Conversely, *Tpo*^{Tg} Eμ-myc mice exhibited delayed illness ($p = 0.0019$) with a median survival of 107 days (Fig. 5a). Moribund mice of all three genotypes had splenomegaly (Fig. 5b) and many presented with elevated blood lymphocyte counts (Table 1) as well as enlarged lymph nodes (Supplementary Fig. 4b). Spleen weights and cellularity were significantly increased in ill *Mpl*^{-/-} Eμ-myc mice when compared to control Eμ-myc mice (Fig. 5b, Supplementary Fig. S4a). The bone marrow revealed diffuse tumor infiltrate of large cells with multiple nucleoli, as well as frequent extravasation into surrounding tissues (Supplementary Fig. S5). The tumor phenotypes, classified as PreB2, immature B-cell or a mixture of the two (mixed), were similarly distributed among the genotypes bearing the Eμ-myc transgene (Fig. 5c). Hematocrit and platelet counts often drop in the late stages of hematological malignancy including in Eμ-myc induced lymphoma (Table 1). Of note, *Mpl*^{-/-} Eμ-myc mice were substantially more anemic than Eμ-myc and *Tpo*^{Tg} Eμ-myc mice (Table 1). At necropsy, lymph node hemorrhage was often observed in *Mpl*^{-/-} Eμ-myc mice, a phenotype not commonly present in the other genotypes (Supplementary Fig. S6).

Enhanced cycling of B-lymphoid cells in pre-neoplastic *Mpl*^{-/-} Eμ-myc mice. Our results support a model in which the pre-malignant phase of Eμ-myc lymphomagenesis is affected by the underlying cellular changes in mice with altered TPO signaling. Since increased B-lymphoid proliferation in pre-malignant Eμ-myc mice is characterized by changes in apoptosis and cell cycling^{19,21}, we examined these processes in the compound mutant mice. Bone marrow cells from 4–5 week old Eμ-myc, *Mpl*^{-/-} Eμ-myc, and *Tpo*^{Tg} Eμ-myc mice were cultured for 24 hours under conditions of cytokine deprivation, and apoptosis was measured in B-cell subsets by Annexin-V binding. In accord with previous studies²¹, Eμ-myc B-cell subsets were highly sensitive to apoptosis compared to wild-type control cells (Supplementary Fig. S7). However, no differences in B-cell apoptosis were observed in *Mpl*^{-/-} Eμ-myc or *Tpo*^{Tg} Eμ-myc cells (Supplementary Fig. S7).

TPO has an established role in the control of HSC number and quiescence^{6,7}, and we confirmed reduced quiescence (G0) in *Mpl*^{-/-} LSKs and conversely increased quiescence in *Tpo*^{Tg} LSKs (Supplementary Fig. S8c). Eμ-myc LSKs expressed *Mpl* to the same extent as wild-type cells (Supplementary Fig. S8a) and similar changes in LSK cell number and cell cycling were observed in *Mpl*^{-/-} and *Tpo*^{Tg} mice in the presence and absence of Eμ-myc (Supplementary Fig. S8b,c). We next investigated if there were differences in cycling of ProB-PreB1, PreB2, immature and mature B-cells in bone marrow and spleen of preneoplastic *Mpl*^{-/-} Eμ-myc, *Tpo*^{Tg} Eμ-myc, and Eμ-myc mice. Previous studies have shown that Eμ-myc mice have more than double the number of PreB cells and mature




Figure 5. TPO delays B-cell lymphoma development in Eμ-myc mice. **(a)** Survival of Eμ-myc (n = 83), Mpl^{-/-} Eμ-myc (n = 200), Tpo^{Tg} Eμ-myc (n = 58), WT (n = 14), Mpl^{-/-} (n = 11) and Tpo^{Tg} (n = 13) mice. P-values were generated with Logrank (Mantel-Cox) test. **(b)** Spleen weight in terminally ill mice and 1-year old control mice. Eμ-myc (n = 47), Mpl^{-/-} Eμ-myc (n = 59), Tpo^{Tg} Eμ-myc (n = 56), WT (n = 5), Mpl^{-/-} (n = 7) and Tpo^{Tg} (n = 6). Whiskers: Min to Max. Statistical significance was generated by Student's unpaired t-test. **p* < 0.05; ***p* < 0.005; ****p* < 0.001. **(c)** Bone marrow disease phenotype in terminally ill mice assessed by flow cytometry. Eμ-myc (n = 31), Mpl^{-/-} Eμ-myc (n = 36) and Tpo^{Tg} Eμ-myc (n = 25) mice.

	WT	Mpl ^{-/-}	Tpo ^{Tg}	Eμ-myc	Mpl ^{-/-} Eμ-myc	Tpo ^{Tg} Eμ-myc
	n = 14	n = 11	n = 13	n = 58	n = 81	n = 62
Platelets (x 10 ⁶ /ml)	1338 ± 245	172 ± 145***	4748 ± 745***	704 ± 283***	31 ± 16***,^^^	2227 ± 951***,^^^
MPV (femtoliter)	7.5 ± 1.3	10.9 ± 4.1**	8.4 ± 1.2	7.3 ± 1.4	11.8 ± 3.2***,^^^	7.3 ± 1.2
Hematocrit (%)	55.0 ± 3.3	49.3 ± 8.9	52.0 ± 3.5	49.2 ± 8.5*	33.6 ± 10.5***,^^^	47.3 ± 4.6**
RBCs (x10 ⁹ /ml)	10.5 ± 0.7	9.6 ± 1.8	9.8 ± 1.4	9.7 ± 1.7	6.2 ± 2.1***,^^^	9.8 ± 0.9
Leukocytes (x10 ⁶ /ml)	8.1 ± 3.2	6.9 ± 2.7	10.2 ± 3.5	57.4 ± 77	35.9 ± 36	87.2 ± 101***
Lymphocytes (x10 ⁶ /ml)	6.3 ± 2.4	5.3 ± 2.2	8.2 ± 3.3	27.7 ± 38	23.0 ± 23	49.5 ± 60***,^^^
Neutrophils (x10 ⁶ /ml)	1.2 ± 0.4	0.8 ± 0.3	1.6 ± 0.6	5.7 ± 4.2**	3.0 ± 2.6^^^	9.9 ± 6.0***,^^^
Monocytes (x10 ⁶ /ml)	0.1 ± 0.0	0.1 ± 0.1	0.2 ± 0.1	0.2 ± 0.3	0.2 ± 0.3	0.7 ± 0.5***,^^^
Eosinophils (x10 ⁶ /ml)	0.3 ± 0.4	0.1 ± 0.1	0.2 ± 0.1	0.2 ± 0.2	0.2 ± 0.2	0.4 ± 0.3^^

Table 1. Peripheral blood counts from ~1 year-old mice (WT, Mpl^{-/-} and Tpo^{Tg}) and terminally ill Eμ-myc mice. Data represent mean ± SD, 1 way ANOVA with Dunnett's multiple comparison test. Significance compared to wild-type (WT) **p* < 0.05; ***p* < 0.005; ****p* < 0.001; significance compared to Eμ-myc ^^*p* < 0.005; ^^*p* < 0.001. Mean platelet volume (MPV), red blood cell (RBCs).

B cells in active cycle compared with controls¹⁹. In keeping with these findings we found an increased proportion of PreB2, immature and mature B-cells in active cycle in Eμ-myc mice compared to healthy controls (Figs 2 and 6). Consistent with our findings in Mpl^{-/-} mice, this effect was augmented in Mpl^{-/-} Eμ-myc PreB2-, immature and mature B-lymphocytes, while a reverse effect was observed in immature and mature B-cells in Tpo^{Tg} Eμ-myc mice, particularly in the spleen (Fig. 6a,b). Thus, the accumulation of B-lymphoid cells in preneoplastic Mpl^{-/-} Eμ-myc mice is likely to be the result of further deregulation of the already increased rate of proliferation of Eμ-myc B-lymphoid cells, with a converse attenuating effect of excess TPO signaling in Tpo^{Tg} Eμ-myc mice.




Figure 6. Increased B-cell cycling in preneoplastic *Mpl*^{-/-} Eμ-*myc* mice. Cell cycle status of (a) bone marrow and (b) spleen B-cell subsets in 4–5 week old Eμ-*myc* (n = 13), *Mpl*^{-/-} Eμ-*myc* (n = 22) and *Tpo*^{Tg} Eμ-*myc* (n = 13) assessed by Ki-67/DAPI staining profiles. Statistical significance was compared to Eμ-*myc*. Statistical significance was generated by Student's unpaired t-test. Mean ± SEM. **p* < 0.05; ***p* < 0.005; ****p* < 0.001.

Discussion

Our findings demonstrated that perturbed TPO signaling had a clear effect on the lymphoid compartment at steady state using genetically modified *Mpl*^{-/-} and *Tpo*^{Tg} models. The earliest stages of the hematopoietic hierarchy where this effect was apparent was observed in *Mpl* expressing LSK cells, where an upregulation of CLP, ProB and PreB gene expression signatures in *Mpl*^{-/-} LSK cells confirmed prior data from Sanjuan-Pla *et al.* that showed an upregulation of lymphoid genes in HSCs from *Tpo*^{-/-} mice, while *Tpo*^{-/-} bone marrow cells gave lymphoid-biased reconstitution when transplanted¹². Together, these data suggest absence of TPO signaling on LSK cells results in lineage priming with enhanced early lymphoid gene expression. In support of the biological significance of the upregulated CLP, ProB and PreB signatures in *Mpl*^{-/-} LSKs, we found an increased number of CLPs in *Mpl*^{-/-} bone marrow. Moreover, we demonstrate that 4–5 week old *Mpl*^{-/-} mice exhibit increased PreB2 and immature B-cell counts in bone marrow and spleen, with an increased proportion of immature and mature splenic B-cells in active cycle. Conversely, elevated TPO signaling in *Tpo*^{Tg} mice negatively affected bone marrow and spleen B-lymphopoiesis. These effects on committed B-lymphoid precursor cell numbers must be indirect, since previous studies, also confirmed here, have shown that while LSK cells express the *Mpl* receptor, CLP and B-cell subsets do not^{11,15,22–24}. The *in vitro* clonogenicity of CLPs from *Mpl*^{-/-} and *Tpo*^{Tg} mice was unaltered, but changes in the cell cycling profiles of B-lymphoid precursor cells correlated with altered cell numbers in these mice. Interestingly, the master erythroid cytokine regulator, EPO, has also been shown, in addition to stimulating erythropoiesis, to negatively affect B-lymphopoiesis at the ProB-cell and PreB-cell stage of maturation, by an indirect mechanism within the bone marrow environment²⁵.

The altered B-lymphopoiesis observed in *Mpl*^{-/-} and *Tpo*^{Tg} bone marrow and spleen was, however, not sufficient to influence lymphocyte counts in the peripheral blood at steady state. Nevertheless, we hypothesized that changes to B-lymphopoiesis evident in mice with altered TPO signaling might have more dramatic consequences in a perturbed system. Thus, we investigated the preneoplastic phase in Eμ-*myc* transgenic mice, which is characterized by increased B-lymphoid cell cycling and lymphocytosis. We observed accumulation of PreB2, immature and mature B-cells in preneoplastic *Mpl*^{-/-} Eμ-*myc* mice relative to that in Eμ-*myc* controls, an effect that was reversed in *Tpo*^{Tg} Eμ-*myc* mice. Furthermore, the effect on preneoplastic Eμ-*myc* mice was also countered by 4 weeks of Romiplostim administration, when mice were 1 to 5 weeks of age. While the increased apoptosis characteristic of Eμ-*myc* B-lymphoid cells²¹ was unaltered in *Mpl*^{-/-} Eμ-*myc* and *Tpo*^{Tg} Eμ-*myc* mice, the increased B-lymphoid cell cycling caused by Eμ-*myc* expression was augmented in *Mpl*^{-/-} Eμ-*myc* mice and attenuated in *Tpo*^{Tg} Eμ-*myc* animals. The effects on the preneoplastic phase in Eμ-*myc* mice were sufficient to influence disease

outcome: illness from B-lymphoma developed with a reduced latency in *Mpl*^{-/-} Eμ-*myc* mice and was delayed in *Tpo*^{Tg} Eμ-*myc* mice. This result is in agreement with a recent study which reported that *Mpl* deficiency increased precursor B-ALL development in the *Lnk*^{-/-} *Tp53*^{-/-} mouse model²⁶.

Our results support a model in which the direct influence of the Eμ-*myc* transgene and the indirect effect of loss of TPO signaling, at least in part due to lymphoid lineage priming in multipotential hematopoietic cells, appear to have an additive effect on cell cycling and accumulation of B-lymphoid populations resulting in an enhanced preneoplastic state and earlier disease onset in *Mpl*^{-/-} Eμ-*myc* mice. The suppressive indirect impact of excess TPO signaling in *Tpo*^{Tg} mice was also evident in the presence of the Eμ-*myc* transgene and could account for the delayed disease initiation in *Tpo*^{Tg} Eμ-*myc* mice. Lymph node intratumor hemorrhage was occasionally observed in terminally ill *Mpl*^{-/-} Eμ-*myc* mice, which is consistent with previous recognition of hemorrhaging of solid tumors in severely thrombocytopenic mice^{27,28}. Thus, while excess bleeding may have contributed to the terminal stage of disease in *Mpl*^{-/-} Eμ-*myc* mice, the significant preneoplastic expansion of splenic B lymphoid cell numbers (PreB2, immature and mature B-cells) and blood lymphocyte counts support a significant contribution by altered B-lymphopoiesis.

While no megakaryocyte-associated fibrosis^{29,30} was observed in 4–5 week old *Tpo*^{Tg} mice (data not shown), our data cannot exclude an effect on B-lymphopoiesis from altered environmental niches or competition for space arising from abnormal megakaryocyte number in the bone marrow and spleen as *Mpl*^{-/-} mice have 10% of normal megakaryocyte and platelet numbers, while *Tpo*^{Tg} mice have ~3.5-fold increased platelet counts with 3-fold elevated bone marrow and spleen megakaryocytes^{7,15,31} (Supplementary Fig. S5b).

In addition, platelets have been shown to protect tumor vasculature²⁸ and to promote hematogenous metastasis in mouse models^{32,33}. Although limited information is available on roles of platelets in lymphoma and leukemia, some recent studies have examined interactions between lymphoma and leukemia cell lines and activated platelets or platelet-released molecules^{34–36}. Although, the present study investigated the preneoplastic phase in Eμ-*myc* mice, future studies are needed to explore potential effects of altered megakaryocyte or platelet numbers that may alter the biological behavior of established lymphoma.

Material and Methods

Mouse. Eμ-*myc*¹⁴, *Mpl*^{-/-}⁶ and *Tpo*^{Tg}⁷ mice have been previously described. All mutations were backcrossed onto the C57BL/6 background for at least 10 generations prior to this study. Experiments include balanced groups of male and female mice if not otherwise stated. Eμ-*myc* mice included in the survival study were taken at an ethical endpoint when displaying lymphadenopathy and/or splenomegaly. All animal experiments complied with the regulatory standards of, and were approved by the Walter and Eliza Hall Institute (WEHI) Animal Ethics Committee.

Peripheral blood counts. Automated cell counts were performed on blood collected from the retro-orbital plexus or by cardiac puncture into Microtainer tubes containing EDTA (Sarstedt, Ingle Farm, SA Australia), using an Advia 2120 hematological analyser (Siemens, Munich Germany).

Progenitor and B-cell subset analysis. 4–5 week old, 1-year old or terminally ill mice were analyzed. Organ processing: Bone marrow was flushed from femurs and tibias in 10 mL of balanced salt solution (BSS; 150 mM NaCl, 3.7 mM KCl, 2.5 mM CaCl₂, 1.2 mM MgSO₄, 7.4 mM HEPES, NaOH, 1.2 mM KH₂PO₄, 0.8 mM K₂HPO₄, pH 7.2) supplemented with 2% fetal calf serum (FCS) and gently pipetted to create a single-cell suspension. Cell suspensions were centrifuged at 1500 g, 5 min at 4°C. Supernatant was then aspirated and the pellet was resuspended in 3 mL of BSS 2% FCS. Cells were filtered using a 100 μm cell strainer. Spleen cell suspensions were prepared by physical dissociation in 3 mL of BSS 2% FCS. Subsequently, 7 mL of Red Cell Removal Buffer (156 mM NH₄Cl, 0.1 mM EDTA, and 12 mM NaHCO₃) was added for 1 min at room temperature. After centrifugation the supernatants were aspirated and the pellet was resuspended in 5 mL of BSS 2% FCS. Cell suspensions were filtered using a 100 μm cell strainer. B-cell populations were defined as ProB-PreB1 (B220⁺ cKit⁺), PreB2 (B220⁺ cKit⁻ IgD⁻ IgM⁻), Immature (B220⁺ cKit⁻ IgD⁻ IgM⁺), Mature (B220⁺ cKit⁻ IgD⁺ IgM⁺), LSK (Lin⁻ Sca1⁺ cKit⁺), LTHSC (Lin⁻ Sca-1⁺ cKit⁺ CD34^{low/-}), STHSC (Lin⁻ Sca-1⁺ cKit⁺ CD34⁺ FLT3⁻), LMPP (Lin⁻ Sca-1⁺ CD34⁺ FLT3⁺), CLP (Lin⁻ Sca-1^{int} cKit^{int} IL7R⁺ FLT3⁺), ALP (Lin⁻ Sca-1^{int} cKit^{int} IL7R⁺ FLT3⁺ Ly6D⁻), BLP (Lin⁻ Sca-1^{int} cKit^{int} IL7R⁺ FLT3⁺ Ly6D⁺). Data was acquired using a LSRFortessa flow cytometer (BD, Franklin Lakes, NY, USA), and data analysis was performed using FlowJo software 10.3.0 (Treestar Inc, Ashland, USA).

LSK gene expression analysis. Gene set tests were performed on microarray data generated from sorted LSK cells from adult wild-type C57BL/6, *Mpl*^{-/-} and *Tpo*^{Tg} mice. Total RNA was hybridized to Illumina MouseWG-6v2 bead chip arrays¹⁵. The microarray data are available at Array express (www.ebi.ac.uk/arrayexpress) under accession no. E-MTAB-2389. Results were normalized using the *neqc*(x) function in limma and gene expression was fitted to the linear model using empirical Bayes and array weights. Gene set tests were performed using gene sets obtained for the CLP, ProB and PreB populations from the Hemopedia atlas (haemosphere.org)¹⁸ using the top 77 upregulated genes for each population compared to the highest gene expression across the entire dataset. Using the Roast function in Limma, a self-contained rotational gene set testing method³⁷, gene set enrichment was tested in *Mpl*^{-/-} and *Tpo*^{Tg} LSKs when compared to wild-type and leading-edge genes contributing to the enriched CLP expression signature in *Mpl*^{-/-} LSK cells, as well as downregulated CLP expression signature in *Tpo*^{Tg} LSK cells, were extracted (Supplementary Table S1).

Analysis of B-lymphoid cell cycling. Single-cell suspensions from bone marrow and spleen of 4–5 week old mice were harvested as described above. Nucleated cell count was performed using trypan blue exclusion and 20 × 10⁶ cells were stained with antibodies to B220 (clone RA3-6B2; BD Pharmingen Franklin Lakes NY USA), CD19 (clone 1D3; ebiosciences San Diego CA USA), c-Kit (clone ACK4; WEHI mAb Facility, Parkville

VIC Australia), IgD (clone 11–26 c.2a; Biolegend San Diego CA USA), and IgM (clone 5.1; WEHI mAb Facility) for 30 min on ice. Cells were then washed with BSS 2% FCS and stained with the appropriate secondary streptavidin-conjugated fluorochromes for another 30 min on ice. Subsequently, cells were fixed and permeabilized with Cytofix/Cytoperm (BD) according to the manufacturer's instruction for 30 min on ice. Cells were then incubated with either FITC-conjugated anti-K_i-67 antibody or the appropriate FITC-conjugated isotype control (BD) overnight at 4 °C. Lastly, 4',6-diamidino-2-phenylindole (DAPI) (10 µg/ml) (Sigma-Aldrich, St. Louis, MO, USA) was added for 30 min at room temperature for analysis of DNA content. Cells were subsequently washed and resuspended with BSS 2% FCS and filtered using 40 µm cell strainer prior to analysis. Data was acquired using a LSR II flow cytometer (BD), and data analysis was performed using FlowJo software. Here, B-cell subsets were defined as: ProB-PreB1 (B220⁺ cKit⁺), PreB2 (B220⁺ CD19⁺ IgD[−] IgM[−]), Immature (B220⁺ CD19⁺ IgD[−] IgM⁺) and Mature (B220⁺ CD19⁺ IgD⁺ IgM⁺).

Romiplostim. At 6–8 days old, E μ -myc mice and their wild-type littermates were injected subcutaneously with 100 µg/kg Romiplostim³⁸ (Nplate[®], Amgen, Thousand Oaks, CA, USA) or saline vehicle. Injections were repeated every 3 days until mice were 5-weeks old.

Statistics. Statistical significance between two treatment groups was analyzed using an unpaired Student's *t* test with two-tailed *p*-values. One-way ANOVA with multiple comparison test was applied where appropriate (GraphPad Prism Version 7). **p* < 0.05; ***p* < 0.005; ****p* < 0.001 or as otherwise stated. Data are presented as mean ± SD or SEM, indicated in figure legends.

Data availability statement. Figure 1 and Tables S1 and S2 have an associated data source. The microarray data are available at Array express (www.ebi.ac.uk/arrayexpress) under accession no. E-MTAB-2389.

References

1. Italiano, J. E. Jr., Patel-Hett, S. & Hartwig, J. H. Mechanics of proplatelet elaboration. *Journal of thrombosis and haemostasis: JTH* 5(Suppl 1), 18–23, <https://doi.org/10.1111/j.1538-7836.2007.02487.x> (2007).
2. Alexander, W. S. Thrombopoietin and the c-Mpl receptor: insights from gene targeting. *Int J Biochem Cell Biol* 31, 1027–1035 (1999).
3. Kuter, D. J. & Rosenberg, R. D. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. *Blood* 85, 2720–2730 (1995).
4. Stoffel, R., Wiestner, A. & Skoda, R. C. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. *Blood* 87, 567–573 (1996).
5. Grozovsky, R. *et al.* The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. *Nature medicine* 21, 47–54, <https://doi.org/10.1038/nm.3770> (2015).
6. Alexander, W. S., Roberts, A. W., Nicola, N. A., Li, R. & Metcalf, D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. *Blood* 87, 2162–2170 (1996).
7. de Graaf, C. A. *et al.* Regulation of hematopoietic stem cells by their mature progeny. *Proceedings of the National Academy of Sciences of the United States of America* 107, 21689–21694, <https://doi.org/10.1073/pnas.1016166108> (2010).
8. Kimura, S., Roberts, A. W., Metcalf, D. & Alexander, W. S. Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. *Proceedings of the National Academy of Sciences of the United States of America* 95, 1195–1200 (1998).
9. Qian, H. *et al.* Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. *Cell Stem Cell* 1, 671–684, <https://doi.org/10.1016/j.stem.2007.10.008> (2007).
10. Yoshihara, H. *et al.* Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. *Cell Stem Cell* 1, 685–697, <https://doi.org/10.1016/j.stem.2007.10.020> (2007).
11. Luc, S. *et al.* Down-regulation of Mpl marks the transition to lymphoid-primed multipotent progenitors with gradual loss of granulocyte-monocyte potential. *Blood* 111, 3424–3434, <https://doi.org/10.1182/blood-2007-08-108324> (2008).
12. Sanjuan-Pla, A. *et al.* Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy. *Nature* 502, 232–236, <https://doi.org/10.1038/nature12495> (2013).
13. Adams, J. M. & Cory, S. Transgenic models of tumor development. *Science* 254, 1161–1167 (1991).
14. Adams, J. M. *et al.* The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. *Nature* 318, 533–538 (1985).
15. Ng, A. P. *et al.* Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation. *Proceedings of the National Academy of Sciences of the United States of America* 111, 5884–5889, <https://doi.org/10.1073/pnas.1404354111> (2014).
16. Ng, S. Y., Yoshida, T., Zhang, J. & Georgopoulos, K. Genome-wide lineage-specific transcriptional networks underscore Ikaros-dependent lymphoid priming in hematopoietic stem cells. *Immunity* 30, 493–507, <https://doi.org/10.1016/j.immuni.2009.01.014> (2009).
17. Mansson, R. *et al.* Molecular evidence for hierarchical transcriptional lineage priming in fetal and adult stem cells and multipotent progenitors. *Immunity* 26, 407–419, <https://doi.org/10.1016/j.immuni.2007.02.013> (2007).
18. de Graaf, C. A. *et al.* Haemopedia: An Expression Atlas of Murine Hematopoietic Cells. *Stem cell reports* 7, 571–582, <https://doi.org/10.1016/j.stemcr.2016.07.007> (2016).
19. Langdon, W. Y., Harris, A. W., Cory, S. & Adams, J. M. The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. *Cell* 47, 11–18 (1986).
20. Kuter, D. J. Romiplostim. *Cancer Treat Res* 157, 267–288, https://doi.org/10.1007/978-1-4419-7073-2_16 (2011).
21. Jacobs, J. J. *et al.* Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. *Genes & development* 13, 2678–2690 (1999).
22. Drexler, H. G. & Quentmeier, H. Thrombopoietin: expression of its receptor MPL and proliferative effects on leukemic cells. *Leukemia* 10, 1405–1421 (1996).
23. Graf, G., Dehmel, U. & Drexler, H. G. Expression of thrombopoietin and thrombopoietin receptor MPL in human leukemia-lymphoma and solid tumor cell lines. *Leukemia research* 20, 831–838 (1996).
24. Erickson-Miller, C. L. *et al.* Thrombopoietin receptor levels in tumor cell lines and primary tumors. *J Oncol* 2010, 135354, <https://doi.org/10.1155/2010/135354> (2010).
25. Singbrant, S. *et al.* Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment. *Blood* 117, 5631–5642, <https://doi.org/10.1182/blood-2010-11-320564> (2011).
26. Cheng, Y. *et al.* LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors. *The Journal of clinical investigation* 126, 1267–1281, <https://doi.org/10.1172/jci81468> (2016).

27. Ho-Tin-Noe, B., Goerge, T., Cifuni, S. M., Duerschmied, D. & Wagner, D. D. Platelet granule secretion continuously prevents intratumor hemorrhage. *Cancer research* **68**, 6851–6858, <https://doi.org/10.1158/0008-5472.can-08-0718> (2008).
28. Ho-Tin-Noe, B., Goerge, T. & Wagner, D. D. Platelets: guardians of tumor vasculature. *Cancer research* **69**, 5623–5626, <https://doi.org/10.1158/0008-5472.can-09-1370> (2009).
29. Abbonante, V. *et al.* Thrombopoietin/TGF-beta1 Loop Regulates Megakaryocyte Extracellular Matrix Component Synthesis. *Stem cells (Dayton, Ohio)* **34**, 1123–1133, <https://doi.org/10.1002/stem.2285> (2016).
30. Kakumitsu, H. *et al.* Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis. *Leukemia research* **29**, 761–769, <https://doi.org/10.1016/j.leukres.2004.12.009> (2005).
31. Lebois, M. *et al.* Regulation of platelet lifespan in the presence and absence of thrombopoietin signaling. *Journal of thrombosis and haemostasis: JTH* **14**, 1882–1887, <https://doi.org/10.1111/jth.13397> (2016).
32. Gay, L. J. & Felding-Habermann, B. Platelets alter tumor cell attributes to propel metastasis: programming in transit. *Cancer cell* **20**, 553–554, <https://doi.org/10.1016/j.ccr.2011.11.001> (2011).
33. Stegner, D., Dutting, S. & Nieswandt, B. Mechanistic explanation for platelet contribution to cancer metastasis. *Thrombosis research* **133**(Suppl 2), S149–157, [https://doi.org/10.1016/s0049-3848\(14\)50025-4](https://doi.org/10.1016/s0049-3848(14)50025-4) (2014).
34. Au, A. E. *et al.* Activated platelets rescue apoptotic cells via paracrine activation of EGFR and DNA-dependent protein kinase. *Cell death & disease* **5**, e1410, <https://doi.org/10.1038/cddis.2014.373> (2014).
35. Velez, J. *et al.* Platelets promote mitochondrial uncoupling and resistance to apoptosis in leukemia cells: a novel paradigm for the bone marrow microenvironment. *Cancer microenvironment: official journal of the International Cancer Microenvironment Society* **7**, 79–90, <https://doi.org/10.1007/s12307-014-0149-3> (2014).
36. Ohana, O. M., Ozer, J., Prinsloo, I., Benharroch, D. & Gopas, J. Hodgkin lymphoma cell lines bind to platelets. Incubation with platelets induces CD15 and P-selectin dependent adhesion of the cell lines to Human Umbilical Vein Endothelial cells (HUVEC). *Cancer biology & therapy* **16**, 1651–1659, <https://doi.org/10.1080/15384047.2015.1095411> (2015).
37. Ng, A. P. *et al.* Early lineage priming by trisomy of Erg leads to myeloproliferation in a Down syndrome model. *PLoS genetics* **11**, e1005211, <https://doi.org/10.1371/journal.pgen.1005211> (2015).
38. Leon, C. *et al.* Romiplostim administration shows reduced megakaryocyte response-capacity and increased myelofibrosis in a mouse model of MYH9-RD. *Blood* **119**, 3333–3341, <https://doi.org/10.1182/blood-2011-08-373811> (2012).

Acknowledgements

The authors thank J. McManus, J. Lochland, S. Lee, L. Cengia, L. Di Rago, K. Stoev and S. Ross for outstanding assistance. This work was supported by grant funds received from the following: Leukaemia Foundation Australia Grant-in-Aid (E.C.J., K.D.M.), Sir Edward Dunlop Medical Research Foundation (E.C.J.), the Australian National Health and Medical Research Council Project Grant (E.C.J. 1079250, A.P.N. 1060179), Program Grant (1016647), Fellowships (W.S.A. 1058344; B.T.K. 1063008; K.D.M. 1090500) and Independent Research Institutes Infrastructure Support Scheme Grant (9000220) and a Victorian State Government Operational Infrastructure Support Grant. E.C.J. is the recipient of a fellowship from the Lorenzo and Pamela Galli Charitable Trust.

Author Contributions

M.L., S.A.S., P.C., J.C., P.G., C.D.H., D.M., A.R., F.Y. and K.D.M. performed research and analyzed data. A.E.A. and A.P.N. designed and performed research, analyzed data, prepared figures and revised the paper. B.T.K. provided reagents and advice. W.S.A. designed research and revised the paper. E.C.J. designed research and wrote the paper. All authors reviewed the manuscript.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-017-15023-2>.

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2017